18/03/2026
🚀 Proud Partner in a 98/100 Scored Horizon Europe Project!
We are thrilled to announce that the MSCA project, “Exploring the Mechanism of Metastasis / Development of New Tests to Enroll Circulating Tumor Cells (CTCs) into Clinical Practice,” has received final approval with an exceptional evaluation score of 98%!
At MBC Labs, we are honored to be part of this elite international consortium coordinated by the University of Patras. This project sits at the absolute frontier of modern oncology, focusing on the transformative potential of liquid biopsy.
🔬 Our Role & Vision
As a dedicated research organization within the consortium, MBC Labs is eager to contribute to the development of innovative diagnostic tools. Our focus will be on:
• Refining the detection and analysis of Circulating Tumor Cells (CTCs).
• Bridging the gap between laboratory research and clinical practice.
• Advancing personalized medicine to ensure cancer patients receive more precise monitoring and tailored treatments.
🌍 A Global Collaborative Effort
Success in science is a team sport. We are proud to collaborate with prestigious academic and research institutions across 7 countries, including partners from Greece, the UK, Germany, Austria, Cyprus, France, and the USA.
Through the MSCA framework, our team looks forward to the cross-border knowledge sharing and interdisciplinary mobility that will undoubtedly spark new breakthroughs in metastasis research.
A sincere thank you to the University of Patras and Professor Galatea Kallergi for their visionary leadership and to all our partners for the hard work that led to this outstanding result.
The journey toward better cancer diagnostics starts now!